In this video blog, Dr. David Perlmutter explains how metabolic syndrome—a cluster of elevated blood pressure, dyslipidemia, increased waist circumference, and impaired blood‑sugar regulation—drives systemic inflammation that contributes to cardiovascular disease, cancer, and brain degeneration. He reviews a recent Neurology study of roughly 1,000 Parkinson’s disease (PD) patients followed for three years, which compared individuals with and without metabolic syndrome using the Unified Parkinson’s Disease Rating Scale (UPDRS). The UPDRS assesses motor function, daily‑living abilities, and medication complications, with higher scores indicating greater disability. Both groups worsened over time, but those with metabolic syndrome showed a markedly faster increase in UPDRS scores, indicating accelerated functional decline. Dr. Perlmutter emphasizes that, unlike symptomatic PD medications, no current drug slows the underlying neurodegeneration, making lifestyle and medical management of metabolic syndrome—blood‑pressure control, weight loss, diet to improve lipid profiles, and blood‑sugar regulation—critical for potentially slowing PD progression. He calls for patients and clinicians to address these modifiable risk factors to improve outcomes across cardiovascular, oncologic, and neurodegenerative diseases.
Chapters
Hello everyone, I'm Dr. David Perlmutter. We've talked quite a bit on these video blogs about the dangerous effects of having what is called metabolic syndrome in terms of various issues in your body. Obviously, the relationship to inflammation by having elevated blood sugar as one of the parts of The metabolic syndrome, the role of inflammation in cardiovascular disease, in cancer, in brain degeneration, for example, including Parkinson's and Alzheimer's. First, let me just redefine what this metabolic syndrome that you're all hearing about really is. It's a constellation of issues including elevated blood pressure, having problems with the blood lipids, which, which we call dyslipidemia, having increased weight circumference, waist circumference, a big belly, and blood sugar control as well. So these, these 4 areas tend to work synergistically to lead to events in the body that promote degeneration, that promote inflammation. We tend to think about metabolic syndrome mostly in terms of it representing a cardiovascular risk issue. But now we're starting to see certain relationships appear relating the metabolic syndrome to brain issues as well. I've recently provided a video blog about the relationship of metabolic syndrome and brain degeneration. Now we see a new report appearing in the journal Neurology entitled Association of Metabolic Syndrome And change in the Unified Parkinson's Disease Rating Scores. And let me break that down. This is a study that looks at the relationship of individuals either who have metabolic syndrome or who do not. All of these people have Parkinson's disease, and it followed these people over a number of years. It was a study of around 1,000 individuals, followed them over 3 years. to determine who degenerated more quickly in terms of what is called the Unified Parkinson's Disease Rating Scale. What this UPDRS is, is a scale that clinicians use to rate how their Parkinson's patients are doing. It looks at a number of issues. It looks at motor function, both subjectively on the part of the patient and objectively, perhaps. on the part of the examiner. It looks at an individual's ability to engage in what are called activities of daily living, self-care. It looks at medication complications, etc. So it's a composite score that indicates perhaps the level of disability rating a Parkinson's patient. The higher the number, the worse the patient seems to be doing. Now, what the study did was, again, looked at Parkinson's patients and compared the those individuals who had metabolic syndrome with those individuals who did not and evaluated them over a 3-year period of time. And what they found was really quite compelling, that over the 3-year period of time, both groups deteriorated in terms of their functionality, but those who were classified as having metabolic syndrome deteriorated much more aggressively. In other words, their score increased much more dramatically. And in fact, you can see that here on this graph. In the upper curve are those individuals who have metabolic syndrome or had metabolic syndrome during the time of the study, and you can certainly appreciate the degree of worsening on their Unified Parkinson's Disease Rating Scale in comparison to those individuals on the bottom part of the curve, The lower graph that shows less deterioration. So the importance of this study is that paying attention to the various parts of the metabolic syndrome in terms of making appropriate lifestyle choices does seem to have an effect on an individual's progression if he or she has Parkinson's disease. You know, the medications that are used for Parkinson's are purely designed to manage the symptom— symptoms. There is no medication that is offered to Parkinson's patients per se that is designed to help with the underlying disease process, i.e., to slow down the rate of degeneration. And here we see that lifestyle choices which affect the development or not of the metabolic syndrome may be really important for that individual. Now we've seen relationships of metabolic syndrome with cardiovascular disease, with risk for various forms of cancer, even with brain degeneration and dementia, and now specifically seeing this report that relates metabolic syndrome to the rate of progression, or decline if you will, in Parkinson's disease. So it is yet another call for gaining control over blood pressure, losing belly fat, and also working on the diet to help improve what we call dyslipidemia, or these inappropriate changes in the blood fats. All of these things can be addressed with lifestyle change, certainly with diet and exercise. Certainly if medications are indicated for the management of high blood pressure or for lowering blood sugar, those are appropriate as well. Well, this is interesting information, and I hope you enjoyed our time together today. We'll talk soon. I'm Dr. David Perlmutter. Bye for now. Bye for now.
